5-(ethylenedioxy)-2-phenylbicyclo<2.2.2>octan-2-ol | 1192365-33-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(ethylenedioxy)-2-phenylbicyclo<2.2.2>octan-2-ol
• 英文别名: 7,10-(1,2-ethylen)-8-phenyl-1,4-dioxaspiro[4,5]decan-8-ol；2'-Phenylspiro[1,3-dioxolane-2,5'-bicyclo[2.2.2]octane]-2'-ol
• CAS: 1192365-33-5
• 化学式: C₁₆H₂₀O₃
• 分子量: 260.333
• InChiKey: NNCFRGDTJLDYGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(ethylenedioxy)-2-phenylbicyclo<2.2.2>octan-2-ol 在 对甲苯磺酸 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 正丁基锂 、 三乙胺 、 N,N-二异丙基乙胺 、 丙酮 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 55.16h， 生成 rac-toluene-4-sulfonic acid (1R*,2R*,4R*)-2-(2-hydroxy-5-phenylbicyclo[2.2.2]oct-5-en-2-yl)ethyl ester
  参考文献：
  名称：

  WO2008/132679

  摘要：

  公开号：
• 作为产物：
  描述：

  双环[2.2.2]辛烷-2,5-二酮 在 对甲苯磺酸 作用下， 以 乙醚 、 环己烷 、 苯 为溶剂， 反应 3.0h， 生成 5-(ethylenedioxy)-2-phenylbicyclo<2.2.2>octan-2-ol
  参考文献：
  名称：

  Stereomutation of 7-tropylionorbornane, 2-tropyliobicyclo[2.2.2]octane, and 2-tropylioadamantane: evidence for the intermediacy of heptafulvenes

  摘要：

  The perchlorates of 7-tropylionorbornane (3), 2-tropyliobicyclo[2.2.2]octane (4), and 2-tropylioadamantane (5) were found to undergo stereomutation in acetonitrile at 25-85-degrees-C, as evidenced by following the change in the C-13 NMR spectra of their deuterium-labeled compounds in acetonitrile-d3. Addition of tetracyanoethylene to their solutions in acetonitrile gave the [8 + 2] cycloaddition products of the corresponding heptafulvenes, indicating the intermediacy of the heptafulvenes. This stereomutation was too slow to detect in dichloromethane at the same temperature. Therefore, it is concluded that the stereomutation proceeds through the abstraction of the alpha-hydrogen by acetonitrile as a base followed by the protonation of the heptafulvene intermediate from the rear side. The entropies of activation which are significantly negative and large indicate abstraction of the alpha-hydrogen is the rate-determining step. The enthalpy of activation for the norbornane system (22.1 +/- 1.1 kcal/mol) is about 8 kcal/mol greater than that for the bicyclo[2.2.2]octane system (15.4 +/- 1.1 kcal/mol) and that for the adamantane system (13.1 +/- 1.3 kcal/mol). Molecular mechanics calculations (MMPI, MM2') for the three heptafulvenes and the corresponding phenyl derivatives (instead of the tropylium ions) indicated that the angle strain at the 8-position of the heptafulvenes controls the rate of the steremutation.

  DOI：

  10.1021/jo00003a028

文献信息

• [EN] SALTS OF ISOBUTYRIC ACID (1 R*, 2R*, 4R* ) -2- (2-{ [3- (4, 7-DIMETH0XY-1 H-BENZOIMIDAZOL-2-YL) -PROPYL] -METHYL-AMINO } -ETHYL) -5-PHENYL-BICYCLO [2.2.2] OCT-5- EN- 2 -YL<br/>[FR] SELS DE L'ESTER DU (1R*,2R*,4R*)-2-(2-{[3-(4,7-DIMÉTHOXY-1H-BENZOIMIDAZOL-2-YL)-PROPYL]-MÉTHYL-AMINO}-ÉTHYL)-5-PHÉNYL-BICYCLO[2.2.2]OCT-5-ÈN-2-YLE DE L'ACIDE ISOBUTYRIQUE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010046857A1

  公开（公告）日：2010-04-29

  The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.

  该发明涉及异丁酸晶体盐（1R*，2R*，4R*）-2-（2-[3-（4,7-二甲氧基-1H-苯并咪唑-2-基）-丙基]-甲基氨基}-乙基）-5-苯基-双环[2.2.2]辛-5-烯-2-基酯，其制备方法，含有所述晶体盐的药物组合物，以及其作为药物的用途，特别是作为钙通道阻滞剂。
• BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Hubler Francis

  公开号：US20110039905A1

  公开（公告）日：2011-02-17

  The invention relates to compounds of formula (I) wherein R 1 represents aryl, which is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and trifluoromethyl; R 2 represents hydrogen, or —CO—R 21 ; R 21 represents (C 1-5 )alkyl, (C 1-3 )fluoroalkyl, or (C 3-6 )cycloalkyl; m represents the integer 2, or 3; p represents the integer 2 or 3; and R 3 represents hydrogen, or (C 1-5 )alkyl; and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  该发明涉及以下式(I)的化合物，其中R1代表芳基，未取代，或者单取代、双取代或三取代，其中取代基独立地选自(C1-4)烷基，(C1-4)氧烷基，卤素和三氟甲基组成的组；R2代表氢，或者—CO—R21；R21代表(C1-5)烷基，(C1-3)氟烷基或(C3-6)环烷基；m表示整数2或3；p表示整数2或3；和R3代表氢，或者(C1-5)烷基；以及这些化合物的药用盐。这些化合物可用作钙通道阻滞剂。
• [EN] BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QUE BLOQUEURS DES CANAUX CALCIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009130679A1

  公开（公告）日：2009-10-29

  The invention relates to compounds of formula (I) wherein R1 represents aryl, which is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl; R2 represents hydrogen, or -CO-R21; R21 represents (C1-5)alkyl, (C1-3)fluoroalkyl, or (C3-6)cycloalkyl; m represents the integer 2, or 3; p represents the integer 2 or 3; and R3 represents hydrogen, or (C1-5)alkyl; and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  该发明涉及具有以下结构的化合物（I），其中R1代表芳基，该芳基未经取代，或者经过单取代、双取代或三取代，其中取代基可独立地选择自（C1-4烷基）、（C1-4）烷氧基、卤素和三氟甲基的组成部分；R2代表氢，或-CO-R21；R21代表（C1-5）烷基、（C1-3）氟烷基或（C3-6）环烷基；m代表整数2或3；p代表整数2或3；R3代表氢，或（C1-5）烷基；以及这些化合物的药用盐。这些化合物可用作钙通道阻滞剂。
• SALTS OF ISOBUTYRIC ACID (1 R*,2R*,4R*) -2- (2- - ETHYL)-5-PHENYL-BICYCLO [2.2.2] OCT-5-EN-2-YL
  申请人：Abele Stefan

  公开号：US20110263667A1

  公开（公告）日：2011-10-27

  The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.

  本发明涉及异丁酸晶体盐（1R*，2R*，4R*）-2-（2-[3-（4,7-二甲氧基-1H-苯并咪唑-2-基）-丙基]-甲基氨基}-乙基）-5-苯基-双环[2.2.2]辛-5-烯-2-基酯，其制备方法，含有所述晶体盐的制药组合物及其作为药物的用途，特别是作为钙通道阻滞剂。
• BRIDGED SIX-MEMBERED RING COMPOUNDS
  申请人：Hilpert Kurt

  公开号：US20100130545A1

  公开（公告）日：2010-05-27

  The invention relates to compounds of formula (I), wherein R 1 , R 2 , R 1a , R 2a , R 3 , R 4 , A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  本发明涉及式(I)的化合物，其中R1、R2、R1a、R2a、R3、R4、A、B、X、W和n如描述中所定义，并且这些化合物的药学上可接受的盐。这些化合物可用作钙通道阻滞剂。